Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: Lord O'Shaughnessy Oral Evidence

Found: Lord O'Shaughnessy: You will be pleased to know that we are having a round table with the Royal Academy

Found: Lord O'Shaughnessy: Yes, indeed, in preparation rather than in response.Leigh Pomlett: Yes, please, or

Found: Lord O'Shaughnessy: It would be good to get your thoughts on whether there are other risks that we are

Found: Lord O'Shaughnessy: Thank you.

Found: Lord O'Shaughnessy: If it is not your secretariat™s responsibility, ought there to be someone somewhere

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS preparedness for the next generation of blood cancer treatments.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

We are committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials, to ensure that innovative, lifesaving treatments are accessible to National Health Service patients, including those with blood cancer.

The Government has also stated that £70 million will be spent on new radiotherapy machines, which will help ensure that the most advanced treatment is available to patients who need it.

In September 2024, Lord Darzi concluded an immediate and independent investigation of the NHS. These findings will help to support improvements across the healthcare system, including through the new 10-Year Health Plan. A core part of this will be our workforce, including the cancer workforce, and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.

In addition, we will develop a new national cancer plan, which will include further details on how we will improve outcomes for cancer patients, including blood cancer.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to tackle barriers teenagers and young adults with cancer face in accessing clinical trials.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

To maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

The Department funds research and research infrastructure, which supports patients and the public to participate in high-quality research across the United Kingdom, through the National Institute of Health and Care Research (NIHR). For children and young people with cancer, this infrastructure includes the Experimental Cancer Medicine Centres, co-funded by the NIHR, Cancer Research UK and the Little Princess Trust, which act as a UK-wide network, bringing together world-leading laboratory and clinical researchers to test new treatments for adults and children with cancer. This includes 12 paediatric phase I/II centres, which function as a single virtual centre to improve patient recruitment and expand geographical access to cancer treatments, tackling some of the barriers to teenagers and young adults accessing cancer clinical trials.

The Department is committed to ensuring clinical trials are people-centred and more accessible, including for teenagers and young adults with cancer. For example, the NIHR provides an online service called 'Be Part of Research' which promotes participation in health and care research by allowing users to search for relevant studies. Young adults aged 18 or over, can consent to be matched to and contacted about relevant studies.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to ensure that teenagers and young adults with cancer have access to specialist psychological support within the 10-year health plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

As part of the work to develop a 10-Year Health Plan, we will carefully be considering policies, including those that impact teenagers and young adults with cancer, with input from the public, patients, health staff, and our partners, as we develop the plan.

We have also launched a significant public engagement process, and we would encourage all those with an interest in the way teenagers and young adults with cancer receive care, and who are aged 16 years old or over, to take part in that process, so that we can fully understand what is not working as well as it should and what the potential solutions are. This can be done via the online portal, which is available at the following link:

https://change.nhs.uk/en-GB/

We plan to run engagement events with children and young people in the new year and are working with the Royal College of Paediatrics and Child Health, the Children’s Commissioner, the National Children’s Bureau, and other partners to ensure we hear from children affected by ill health.

Following publication of the 10-Year Health Plan, the Department will publish a National Cancer Plan. We are committed to ensuring that the needs of children and young people with cancer are carefully considered in the National Cancer Plan, and will set out further details in due course.

In order to maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that teenagers and young adults with cancer have access to clinical trials within the 10-year Health plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

As part of the work to develop a 10-Year Health Plan, we will carefully be considering policies, including those that impact teenagers and young adults with cancer, with input from the public, patients, health staff, and our partners, as we develop the plan.

We have also launched a significant public engagement process, and we would encourage all those with an interest in the way teenagers and young adults with cancer receive care, and who are aged 16 years old or over, to take part in that process, so that we can fully understand what is not working as well as it should and what the potential solutions are. This can be done via the online portal, which is available at the following link:

https://change.nhs.uk/en-GB/

We plan to run engagement events with children and young people in the new year and are working with the Royal College of Paediatrics and Child Health, the Children’s Commissioner, the National Children’s Bureau, and other partners to ensure we hear from children affected by ill health.

Following publication of the 10-Year Health Plan, the Department will publish a National Cancer Plan. We are committed to ensuring that the needs of children and young people with cancer are carefully considered in the National Cancer Plan, and will set out further details in due course.

In order to maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department will take to improve the speed of diagnosis for teenagers and young adults with cancer within the 10-year Health plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

As part of the work to develop a 10-Year Health Plan, we will carefully be considering policies, including those that impact teenagers and young adults with cancer, with input from the public, patients, health staff, and our partners, as we develop the plan.

We have also launched a significant public engagement process, and we would encourage all those with an interest in the way teenagers and young adults with cancer receive care, and who are aged 16 years old or over, to take part in that process, so that we can fully understand what is not working as well as it should and what the potential solutions are. This can be done via the online portal, which is available at the following link:

https://change.nhs.uk/en-GB/

We plan to run engagement events with children and young people in the new year and are working with the Royal College of Paediatrics and Child Health, the Children’s Commissioner, the National Children’s Bureau, and other partners to ensure we hear from children affected by ill health.

Following publication of the 10-Year Health Plan, the Department will publish a National Cancer Plan. We are committed to ensuring that the needs of children and young people with cancer are carefully considered in the National Cancer Plan, and will set out further details in due course.

In order to maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure that the specific issues faced by teenagers and young adults with cancer are accounted for in the 10-Year Health Plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

As part of the work to develop a 10-Year Health Plan, we will carefully be considering policies, including those that impact teenagers and young adults with cancer, with input from the public, patients, health staff, and our partners, as we develop the plan.

We have also launched a significant public engagement process, and we would encourage all those with an interest in the way teenagers and young adults with cancer receive care, and who are aged 16 years old or over, to take part in that process, so that we can fully understand what is not working as well as it should and what the potential solutions are. This can be done via the online portal, which is available at the following link:

https://change.nhs.uk/en-GB/

We plan to run engagement events with children and young people in the new year and are working with the Royal College of Paediatrics and Child Health, the Children’s Commissioner, the National Children’s Bureau, and other partners to ensure we hear from children affected by ill health.

Following publication of the 10-Year Health Plan, the Department will publish a National Cancer Plan. We are committed to ensuring that the needs of children and young people with cancer are carefully considered in the National Cancer Plan, and will set out further details in due course.

In order to maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to consult teenagers and young adults with cancer on the 10-year Health plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

As part of the work to develop a 10-Year Health Plan, we will carefully be considering policies, including those that impact teenagers and young adults with cancer, with input from the public, patients, health staff, and our partners, as we develop the plan.

We have also launched a significant public engagement process, and we would encourage all those with an interest in the way teenagers and young adults with cancer receive care, and who are aged 16 years old or over, to take part in that process, so that we can fully understand what is not working as well as it should and what the potential solutions are. This can be done via the online portal, which is available at the following link:

https://change.nhs.uk/en-GB/

We plan to run engagement events with children and young people in the new year and are working with the Royal College of Paediatrics and Child Health, the Children’s Commissioner, the National Children’s Bureau, and other partners to ensure we hear from children affected by ill health.

Following publication of the 10-Year Health Plan, the Department will publish a National Cancer Plan. We are committed to ensuring that the needs of children and young people with cancer are carefully considered in the National Cancer Plan, and will set out further details in due course.

In order to maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking or plan to take to increase the volume of clinical research undertaken within NHS England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department funds research and research infrastructure, which supports patients and the public to participate in high-quality research across the United Kingdom, through the National Institute of Health and Care Research (NIHR).

Development and delivery of research in the pharmaceutical sector is supported and enabled nationwide through NIHR infrastructure, including the NIHR Research Delivery Network, the NIHR Clinical Research Facilities, the NIHR Biomedical Research Centres, and the newly designated NIHR Commercial Research Delivery Centres. These all support the delivery of clinical research through facilities, staff resource, collaborations, and funding.

In order to maximise our potential to be a world leader and develop a more competitive, efficient, and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the UK, to provide innovative treatment options for patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to carry out Vorasidenib trials on patients that have undergone (a) radiotherapy and (b) chemotherapy.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

Research is crucial in tackling brain cancer, which is why the Department spends £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer as one of the largest areas of investment, at over £121.8 million in 2022/23, reflecting its high priority.

The NIHR welcomes funding applications for research into any aspect of human health, including clinical trials for brain cancer treatments. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

The Department aims to ensure that all patients, including those with brain tumours, have access to cutting-edge clinical research and innovative, lifesaving treatments. In order to maximise our potential to be a world leader and develop a more competitive, efficient, and accessible clinical research system, the Department is committed to rapidly implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials, and going further in our support for the forthcoming 10-Year Health Plan.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make it his policy to implement the recommendations of Blood Cancer UK's Action Plan.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancer, as quickly as possible to treat it faster and to improve outcomes. This is supported by NHS England’s key ambition on cancer to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out.

The Department is committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials making sure that the United Kingdom leads the world in clinical trials, and to ensure that innovative, lifesaving treatments are accessible to NHS patients, including those with blood cancer.

Professor Lord Darzi has undertaken an independent investigation into the state of the NHS, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. The Government will therefore set out any further priorities on cancer and health in due course.

I would be happy to meet the Hon. member to discuss the Blood Cancer UK Action Plan.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential implications for his Department's policies of the recommendations of Blood Cancer UK's Action Plan.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Department has not made a formal assessment of the potential implications of its policies based on the recommendations of Blood Cancer UK’s Action Plan.

However, we will get the National Health Service diagnosing cancer earlier and treating it faster. This is supported by NHS England’s key ambition on cancer to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out.

The Department is committed to implementing the recommendations of the Lord O'Shaughnessy review into commercial clinical trials, making sure that the United Kingdom leads the world in clinical trials, and to ensure that innovative, lifesaving treatments are accessible to NHS patients, including those with blood cancer.

Professor Lord Darzi has undertaken an independent investigation into the state of the NHS, the findings of which will feed into the Government’s 10-year plan to build a health service that is fit for the future. The Government will therefore set out any further priorities on cancer and health in due course.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled Full government response to the Lord O'Shaughnessy review into commercial clinical trials, last updated on 8 December 2023, what her Department's planned timetable is for expanding the national contract value review programme to phase 1 and 2a clinical trials.

Answered by Andrew Stephenson

The National Contract Value Review (NCVR) process applies to commercial clinical studies. NHS England is working in partnership with the devolved administrations, the National Institute for Health and Care Research, and other partners, to pilot the use of the NCVR process for phase I and IIa of commercial clinical trials. The ambition is to make the use of NCVR for phase I and IIa of commercial clinical trials mainstream from October 2024.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department has taken to implement the (a) significant actions under problem statement 6 and (b) other recommendations of the Lord O'Shaughnessy review of commercial clinical trials.

Answered by Andrew Stephenson

The Government will soon publish a full response to the Lord O’Shaughnessy independent review into commercial clinical trials.

The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023 as well as all other recommendations in the review.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 6 April 2017 (HL6515), whether the Human Fertilisation and Embryology Authority has been made aware that any child born as a result of mitochondrial donation has (1) a mitochondrial disease, (2) birth defect, (3) genetic abnormality, or (4) any other adverse outcome.

Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)

The Human Fertilisation and Embryology Authority has advised that it cannot provide the detailed information as requested as it may compromise patient confidentiality.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, how many staff from the Department of (a) Science, Innovation and Technology, (b) Health and Social Care and (c) Business and Trade will be involved in the review.

Answered by George Freeman

The Office for Life Sciences is providing secretariat support for the review and is a joint unit between Department for Health and Social Care and Department for Science, Innovation and Technology. Three members of OLS staff are involved in this secretariat function as part of their roles. No members of the Department for Business and Trade are providing direct support. Officials from both DHSC and DSIT are providing evidence for the review as experts in Clinical Research.

Question to the Department for Science, Innovation & Technology:

To ask Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, what the salary for leading the review is.

Answered by George Freeman

Lord O’Shaughnessy has been appointed as Chair for the independent review into UK clinical trials. Lord O’Shaughnessy is not a government official and the role is unpaid.

Question to the Department for Science, Innovation & Technology:

To ask Secretary of State for Science, Innovation and Technology, with reference to the press release entitled Lord O'Shaughnessy to lead independent review into UK clinical trials, published on 20 February 2023, what budget her Department has allocated to the review.

Answered by George Freeman

No specific budget has been allocated to the review. Existing staff have been temporarily re-allocated in order to support the running of the review.

Found: Answering member: Lord O'Shaughnessy | Department: Department of Health and Social Care The Government

Found: In 2023-24 DHSC published an implementation plan in response to the Lord O'Shaughnessy review into

Found: In 2023-24 DHSC published an implementation plan in response to the Lord O'Shaughnessy review into

Found: The Lord O'Shaughnessy review into commercial clinical trials in the UK ( 8) was commissioned by the

Found: response to the review into commercial clinical trials The full government response to the Lord O'Shaughnessy

Found: Full government response to the Lord O'Shaughnessy review into commercial clinical trials. 40p.

Found: Asked for her views on the recently published Lord O'Shaughnessy report which makes a series of re